299 related articles for article (PubMed ID: 16924387)
21. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
[TBL] [Abstract][Full Text] [Related]
22. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.
Hamdy SI; Hiratsuka M; Narahara K; El-Enany M; Moursi N; Ahmed MS; Mizugaki M
Br J Clin Pharmacol; 2002 Jun; 53(6):596-603. PubMed ID: 12047484
[TBL] [Abstract][Full Text] [Related]
23. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
24. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K
Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152
[TBL] [Abstract][Full Text] [Related]
25. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.
Yokoi T; Kamataki T
Pharm Res; 1998 Apr; 15(4):517-24. PubMed ID: 9587945
[TBL] [Abstract][Full Text] [Related]
26. Applications of CYP450 testing in the clinical setting.
Samer CF; Lorenzini KI; Rollason V; Daali Y; Desmeules JA
Mol Diagn Ther; 2013 Jun; 17(3):165-84. PubMed ID: 23588782
[TBL] [Abstract][Full Text] [Related]
27. The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children.
Seven M; Batar B; Unal S; Yesil G; Yuksel A; Guven M
Mol Diagn Ther; 2014 Apr; 18(2):229-36. PubMed ID: 24338437
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements.
Saraeva RB; Paskaleva ID; Doncheva E; Eap CB; Ganev VS
J Clin Pharm Ther; 2007 Dec; 32(6):641-9. PubMed ID: 18021343
[TBL] [Abstract][Full Text] [Related]
29. Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population.
Céspedes-Garro C; Rodrigues-Soares F; Jiménez-Arce G; Naranjo MG; Tarazona-Santos E; Fariñas H; Barrantes R; Llerena A;
Rev Biol Trop; 2016 Sep; 64(3):1067-76. PubMed ID: 29461783
[TBL] [Abstract][Full Text] [Related]
30. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
[TBL] [Abstract][Full Text] [Related]
31. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population.
Kimura M; Ieiri I; Mamiya K; Urae A; Higuchi S
Ther Drug Monit; 1998 Jun; 20(3):243-7. PubMed ID: 9631918
[TBL] [Abstract][Full Text] [Related]
32. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
[TBL] [Abstract][Full Text] [Related]
33. Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese.
Zhou Q; Yu XM; Lin HB; Wang L; Yun QZ; Hu SN; Wang DM
Pharmacogenomics J; 2009 Dec; 9(6):380-94. PubMed ID: 19636337
[TBL] [Abstract][Full Text] [Related]
34. Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population.
Hilli J; Rane A; Lundgren S; Bertilsson L; Laine K
Fundam Clin Pharmacol; 2007 Aug; 21(4):379-86. PubMed ID: 17635176
[TBL] [Abstract][Full Text] [Related]
35. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Roots I; Brockmöller J
Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109
[TBL] [Abstract][Full Text] [Related]
36. Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy.
López-García MA; Feria-Romero IA; Serrano H; Rayo-Mares D; Fagiolino P; Vázquez M; Escamilla-Núñez C; Grijalva I; Escalante-Santiago D; Orozco-Suarez S
Pharmacol Rep; 2017 Jun; 69(3):504-511. PubMed ID: 28343093
[TBL] [Abstract][Full Text] [Related]
37. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.
Skadrić I; Stojković O
Int J Legal Med; 2020 Mar; 134(2):433-439. PubMed ID: 31858263
[TBL] [Abstract][Full Text] [Related]
38. Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population.
Tang SW; Lv XZ; Chen R; Wu SS; Yang ZR; Chen DF; Zhan SY
Clin Exp Pharmacol Physiol; 2013 May; 40(5):326-32. PubMed ID: 23469989
[TBL] [Abstract][Full Text] [Related]
39. Pilot study for the characterization of pharmacogenetically relevant CYP2D6, CYP2C19 and ABCB1 gene polymorphisms in the Hungarian population.
Rideg O; Háber A; Botz L; Szücs F; Várnai R; Miseta A; Kovács GL
Cell Biochem Funct; 2011 Oct; 29(7):562-8. PubMed ID: 21826689
[TBL] [Abstract][Full Text] [Related]
40. Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus?
Kragelund C; Hansen C; Reibel J; Nauntofte B; Broesen K; Pedersen AM; Smidt D; Eiberg H; Torpet LA
J Oral Pathol Med; 2009 Jan; 38(1):63-71. PubMed ID: 19192051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
